Joel Lewis - Jan 24, 2024 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Signature
Jack W. Callicutt, by power of attorney
Stock symbol
GALT
Transactions as of
Jan 24, 2024
Transactions value $
$0
Form type
4
Date filed
2/7/2024, 04:48 PM
Previous filing
Jan 2, 2024
Next filing
Mar 4, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Stock Option (right to buy) Award $0 +91K $0.00 91K Jan 24, 2024 Common Stock 91K $1.72 Direct F1, F2
transaction GALT Restricted Stock Unit Award $0 +56K $0.00 56K Jan 24, 2024 Common Stock 56K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2 The options vest as follows: 25% on each of June 30, 2024; December 31, 2024; June 30, 2025; and December 31, 2025.
F3 The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.
F4 Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested.